Enhabit (NYSE:EHAB - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.03), Zacks reports. Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%.
Shares of EHAB traded up $0.08 during midday trading on Wednesday, hitting $8.55. 305,901 shares of the company traded hands, compared to its average volume of 276,512. Enhabit has a 52 week low of $6.85 and a 52 week high of $11.74. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. The firm has a 50 day moving average of $8.16 and a 200-day moving average of $7.90. The stock has a market cap of $430.13 million, a price-to-earnings ratio of -3.69 and a beta of 1.83.
In other news, Director Jeffrey Bolton bought 4,000 shares of Enhabit stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $8.69 per share, with a total value of $34,760.00. Following the completion of the purchase, the director now owns 98,144 shares in the company, valued at $852,871.36. The trade was a 4.25 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Stuart M. Mcguigan bought 15,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was purchased at an average price of $8.81 per share, with a total value of $132,150.00. Following the acquisition, the director now directly owns 46,810 shares in the company, valued at approximately $412,396.10. The trade was a 47.15 % increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is owned by corporate insiders.
A number of research analysts have recently weighed in on the company. Jefferies Financial Group raised Enhabit from a "hold" rating to a "buy" rating and lifted their price objective for the company from $8.25 to $9.50 in a research report on Monday, December 9th. Leerink Partners reiterated a "market perform" rating and issued a $8.00 price target (down from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $8.75.
Check Out Our Latest Stock Analysis on EHAB
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Enhabit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enhabit wasn't on the list.
While Enhabit currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.